(Bloomberg) — Members of Congress are pushing to revise an Obama-era rule that barred some dialysis patients from getting aid from industry-backed charities, a change that could also make it easier for kidney care companies to steer those patients into insurance plans that pay the companies better.
Patients with end-stage kidney disease who need dialysis are typically covered under Medicare or Medicaid. Those U.S. government programs reimburse dialysis providers including Fresenius SE and DaVita Inc. at lower rates than private insurance does. Before a 2014 rule, companies would sometimes help patients apply to industry-funded charities that helped finance patients’ insurance premiums to get them into better-reimbursing private plans under the Affordable Care Act.
While patients in the ACA plans can have lower out-of-pocket costs, the insurers ended up paying the dialysis facilities “tens or even hundreds of thousands of dollars more per patient,” according to an analysis by the U.S. last year.
In a letter sent to Health and Human Services Secretary Tom Price Wednesday, members of Congress asked the Trump administration to revise a 2014 policy that let health insurers with individual major medical coverage bar people from paying their insurance premiums using patient assistance programs. Revising the rule could make it easier for dialysis companies to steer patients to private plans, though the letter urges HHS to make sure patients aren’t swayed by others’ financial interests.
In 2013, Medicare and Medicaid covered about 376,000 end-stage renal disease patients who needed dialysis to assist their failing kidneys, at the cost of $11.7 billion, according to a government report.
Support in Congress
The letter was signed by members of Congress led by Reps. Kevin Cramer, a North Dakota Republican, and Doris Matsui, a California Democrat. Cramer said in a news release that insurers in at least 41 states had adopted bans on the premium assistance.
The Obama-era policy has encouraged plans “to discriminate against Americans with rare diseases, chronic illnesses and other catastrophic conditions by rejecting them on the basis of the insurance-premium and cost-sharing assistance that they receive from nonprofit organizations,” the lawmakers said in the letter. “This practice essentially allows insurers to ‘steer’ patients to the government or to other plans to avoid providing coverage.”
Davita shares gained 1.3% to $66.07 at 11:03 a.m. in New York. Fresenius shares were up 1.6% to 76.71 euros as of 5:01 p.m. in Frankfurt.
Patient charities often also help with drug prescription co-pays and have come under increasing scrutiny over whether their assistance actually raises medical costs by helping for-profit companies get their products and services used and reimbursed by government programs and insurers.
Alleigh Marre, a spokeswoman for HHS, declined to comment. Health insurers have said the patient charity programs can create conflicts of interest and put sicker patients into the ACA public exchange system, raising insurance premiums for other patients, instead of using Medicare and Medicaid as a backstop.